Welcome to our dedicated page for Optimizerx news (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on Optimizerx stock.
OptimizeRx Corp (NASDAQ: OPRX) provides a dedicated news hub for tracking developments in healthcare technology and digital patient engagement solutions. This page aggregates official announcements, financial disclosures, and strategic updates from the leader in EHR-integrated pharma messaging.
Investors and industry professionals will find curated coverage of earnings reports, technology partnerships, product launches, and regulatory milestones. The resource serves as a centralized source for understanding OPRX's role in connecting pharmaceutical companies with healthcare providers through cloud-based communication platforms.
Key content categories include financial results, strategic alliances with EHR providers, technology innovations in digital health messaging, and industry recognition of platform advancements. All materials maintain factual accuracy and timeliness required for informed decision-making.
Bookmark this page for streamlined access to OptimizeRx's evolving position in medication adherence solutions and AI-driven healthcare communications. Regular updates ensure stakeholders stay informed about developments impacting the digital pharma marketing landscape.
OptimizeRx Corp (Nasdaq: OPRX) announces a conference call on May 4, 2022, at 4:30 p.m. Eastern Time to discuss its first-quarter financial results for the period ending March 31, 2022. A press release with the financial results will precede the call. Participants can join by telephone or webcast, with a replay available for 12 months on the company’s website. OptimizeRx provides point-of-care technology solutions, connecting healthcare providers and patients to enhance medication adherence.
OptimizeRx has announced the acquisition of EvinceMed, enhancing its point-of-care technology solutions to improve access to specialty medications for patients. This strategic acquisition strengthens OptimizeRx's platform, which connects over 700,000 healthcare providers, enabling faster patient access to therapies through process automation. Specialty drugs, while only 2.2% of prescriptions, accounted for over 45% of pharmacy spending in 2019, highlighting a significant market opportunity. The integration aims to increase revenue growth in 2023 and improve workflows for healthcare providers.
OptimizeRx Corp (Nasdaq: OPRX) announced that its Senior VP of Corporate Finance, Andy D'Silva, will participate in the 34th Annual ROTH Conference from March 13-15, 2022, in Dana Point, CA. D'Silva will engage in one-on-one and small group meetings with investors on March 14-15. The conference includes discussions on various growth sectors, featuring approximately 400 companies. OptimizeRx connects over 60% of U.S. healthcare providers, facilitating patient engagement and therapy adherence through its technology platform.
OptimizeRx Corp. (Nasdaq: OPRX) reported a 24% increase in Q4 2021 revenues, reaching $20.3 million, with a gross profit margin of 61%. Full-year revenue rose 42% to $61.3 million. The company achieved a net income of $0.6 million in Q4, down from $1.4 million in the previous year, while non-GAAP net income improved to $4.0 million. The firm anticipates 2022 revenue between $80 million and $85 million, reflecting growth between 31% and 39%.
OptimizeRx Corp (Nasdaq: OPRX) reported preliminary financial results for Q4 2021, anticipating revenues of approximately $20.3 million, marking a 42% increase year-over-year. The company achieved a GAAP net income of $0.6 million and a record adjusted EBITDA of $4.0 million. As part of its growth strategy, OptimizeRx introduced new KPIs focused on customer penetration within the top pharmaceutical manufacturers and aims for 2022 revenues between $80 million to $85 million, projecting 31% to 39% growth.
FAQ
What is the current stock price of Optimizerx (OPRX)?
What is the market cap of Optimizerx (OPRX)?
